Testing a new medication to reduce inflammation in people with controlled HIV

Plain-English translation of NCT07030920 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

Even when HIV is well-controlled with current medications, some people experience ongoing inflammation and early health problems like heart disease. This study tests whether adding , a medication that blocks hidden viral particles from triggering inflammation, can improve overall health. You would take this medication daily for 24 months alongside your current HIV treatment.

People with controlled HIV still develop serious health conditions earlier than expected, possibly because tiny viral particles continue to cause inflammation in their body. This medication is designed to stop those hidden particles from causing damage, potentially preventing heart disease, cognitive decline, and other age-related illnesses.

Do you qualify?

You likely qualify if…

you are 40 years or older, or have lived with HIV for 25 years or more
your HIV viral load has been undetectable (below 50 copies per milliliter) for at least the last 6 months
you have at least one cardiovascular risk factor, such as high blood pressure, diabetes, a smoking history, high cholesterol, or a family history of early heart disease
you have detectable levels of a specific hidden viral particle (sgp120) in your blood within the past year
if you have had a past heart attack or stroke, you are in stable condition at least 3 months after the event

You likely don't qualify if…

you are allergic to fostemsavir or any of its ingredients
you are pregnant, planning to become pregnant, or breastfeeding
you are taking certain medications (especially anticonvulsants, rifampicin, or St. John's wort) that interfere with how this medication works
you have serious liver disease with signs like fluid buildup in the abdomen, brain problems, or severely abnormal blood tests
you have a heart rhythm condition called long QT syndrome or are taking medications that affect your heart's electrical system

What participation looks like

If you join this study, you would be randomly assigned to either take the new medication ( 600 mg) once daily in addition to your current HIV medications, or continue with your current treatment only. You would participate for 24 months, attending regular study visits where doctors monitor your inflammation levels, heart health, and overall wellness. The study will also include imaging scans and blood tests to track how the medication affects your body.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(1 site)

Canada

CR CHUM, Montreal, Quebec